Indian pharmaceutical company Alkem Laboratories has launched Cetuxa, the world’s first biosimilar of Cetuximab, which is used to treat head and neck cancer. The medication will be administered as an intravenous infusion and is available in a single-dose vial. Alkem Laboratories aims to make the therapy more affordable, accessible, and available to a larger number of critically ill cancer patients. The company’s managing director, Sandeep Singh, explained that the high cost of the treatment limited its reach in India, and therefore, his firm launched the affordable biosimilar backed by indigenous research and production. Head and neck cancer is one of the leading types of cancer in India, primarily caused by the consumption of tobacco.
Alkem Laboratories is a multinational pharmaceutical company headquartered in Mumbai, India. The firm is involved in the research and development, production, and marketing of pharmaceutical drugs.
Sandeep Singh is the managing director of Alkem Laboratories, one of the leading pharmaceutical companies in India. Singh was appointed as the CEO of the company in 2013 and has been instrumental in growing the firm’s revenue. Prior to his current role, Singh worked as the company’s executive director and was responsible for the company’s pharmaceutical operations.